Particle.news
Download on the App Store
20 ARTICLES
·
13h ago

AstraZeneca Pledges $50 Billion by 2030 to Expand U.S. Manufacturing Under Tariff Probe

The plan centers on a flagship Virginia drug substance plant with expansions in five states as a Section 232 investigation presses firms to shore up domestic pharmaceutical supply

AstraZeneca CEO Pascal Soriot.
A sign is pictured during the unveiling of AstraZeneca's new manufacturing facility, to be operational in the coming months with an initial focus on T-cell therapies, in Rockville, Maryland, U.S., May 5, 2025. REUTERS/Jonathan Ernst/File Photo
Image
Image

Overview

  • AstraZeneca will invest $50 billion in U.S. manufacturing and research by 2030 to enhance domestic drug production.
  • The centerpiece is a Virginia drug substance plant, which will be the company’s largest global manufacturing investment for weight-loss and metabolic compounds.
  • Additional R&D and cell therapy manufacturing expansions are planned in Maryland, Massachusetts, California, Indiana and Texas alongside clinical trial network upgrades.
  • The plan supports AstraZeneca’s target of $80 billion in annual revenue by 2030 with half of sales coming from the United States, which contributed over 40% of revenue in 2024.
  • The move responds to President Trump’s Section 232 probe into pharmaceutical imports and is projected to create tens of thousands of U.S. jobs.